Japan PPI inflation slips to 11-mth low in July
Heron Therapeutics, Inc. (NASDAQ:HRTX) announced it has entered into a Framework Agreement with Patheon Austria GmbH & Co KG and Thermo Fisher Scientific Inc (NYSE:TMO)., according to a statement made in a Securities and Exchange Commission filing.
Under the terms of the agreement, signed Wednesday, Patheon will manufacture and supply specific quantities of certain products for Heron Therapeutics. Heron has committed to purchase 38,400 kilograms of these products through December 31, 2026. In addition to manufacturing, Patheon will continue to conduct ongoing stability studies related to the products and provide warehousing services. With analysts setting price targets between $3 and $6, significantly above current trading levels, InvestingPro subscribers can access 8 additional key insights about Heron’s financial health and market position.
The agreement also includes the termination of certain previous agreements between Heron and Patheon, along with the resolution of related historical obligations. The Framework Agreement is subject to the terms of a previously established Manufacturing and Supply Agreement, which has been amended as part of the new arrangement. This amended agreement outlines the general terms for Patheon’s manufacturing services and performance of stability studies for Heron.
Heron Therapeutics is a pharmaceutical company based in San Diego, California. The information in this article is based on a press release statement included in the company’s SEC filing.
In other recent news, Heron Therapeutics reported its Q2 2025 earnings, which fell short of analyst expectations. The company announced an earnings per share (EPS) of -0.02 USD, missing the anticipated -0.01 USD. Additionally, Heron Therapeutics reported revenues of 37.2 million USD, which was below the forecasted 38.08 million USD. These results have raised concerns among investors, as reflected in the market’s reaction. The company’s performance has been closely monitored by analysts, and the recent earnings miss adds to the scrutiny. While specific analyst upgrades or downgrades were not mentioned, such developments often influence investor sentiment. These earnings results are part of the recent developments surrounding Heron Therapeutics. The company’s financial performance remains a focal point for market observers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.